TAF
NKTR icon

Tredje AP-fonden’s Nektar Therapeutics NKTR Stock Holding History

Tredje AP-fonden’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-599
Closed -$194K – 359
2019
Q4 		$194K Sell
599
-400
-40% -$116K 0.01% 391
2019
Q3 		$273K Buy
999
+515
+106% +$189K 0.01% 386
2019
Q2 		$258K Sell
484
-592
-55% -$297K 0.01% 396
2019
Q1 		$542K Buy
1,076
+216
+25% +$128K 0.03% 361
2018
Q4 		$424K Buy
860
+653
+315% +$394K 0.03% 346
2018
Q3 		$189K Buy
+207
New +$177K 0.01% 383

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Tredje AP-fonden's NKTR Position: Q1 2020 in Review

Tredje AP-fonden sold out of Nektar Therapeutics (NKTR) in Q1 2020, closing a stake of 599 shares — an estimated $194K sold.

Tredje AP-fonden first reported a position in NKTR in Q3 2018 and held it in 6 quarters. The position peaked at $542K in Q1 2019. 245 funds tracked by Wall St. Rank hold NKTR as of Q1 2020.

  • Tredje AP-fonden reported no remaining Nektar Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Tredje AP-fonden sold 599 Nektar Therapeutics shares in Q1 2020, an estimated $194K.
  • Tredje AP-fonden first reported a position in Nektar Therapeutics in Q3 2018 and held it in 6 quarters.
  • Tredje AP-fonden's Nektar Therapeutics position peaked at $542K in Q1 2019.
  • 245 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2020.

Based on Tredje AP-fonden's 13F filing for Q1 2020, filed 11 May 2020.